title: Treatment and outcomes of acute coronary syndrome in the cancer population.
abstract: BACKGROUND
  Randomized trials have established the benefit of medical therapy and revascularization in the treatment of acute myocardial infarction (MI). Cancer and cardiovascular disease are the 2 most common diseases worldwide. In clinical practice, cancer patients are frequently afflicted with MI. The benefit of medical and/or revascularization therapy in the cancer population with MI is less well known.
  
  
  OBJECTIVE
  Medical and revascularization therapy reduces mortality in cancer patients with MI.
  
  
  METHODS
  After approval by the institutional review board, we retrospectively reviewed all patients with a discharge diagnosis of acute MI who were admitted to the University of Texas MD Anderson Cancer Center between December 2000 and October 2006 and evaluated the association between cardiac treatments with survival outcomes.
  
  
  RESULTS
  A total of 456 patients with a discharge diagnosis of acute MI were identified and included in the study, of which 386 had non-ST-segment elevation MI (NSTEMI) and 70 had ST-segment elevation MI (STEMI). Compared with patients with NSTEMI, patients who had STEMI were more often prescribed aspirin (66% vs 43%; P = 0.004), β-blockers (61% vs 46%; P = 0.018), and thrombolytic therapy (9% vs 0.3%; P = 0.0001). In the multivariable analysis, aspirin use was associated with a 23% decreased risk of death (hazard ratio [HR]: 0.77, 95% confidence interval [CI]: 0.60-0.98, P = 0.033) and β-blocker use was associated with a 36% decreased risk of death (HR: 0.64, 95% CI: 0.51-0.81, P = 0.0002). Statins (HR: 0.82, P = 0.18) and catheter-based revascularization (HR: 0.57, P = 0.09) did not have an impact on the risk of death. Compared with patients with limited cancer, advanced cancer patients were twice as likely to die (HR: 2.12, 95 CI: 1.47-3.04, P < 0.0001). Previous chemotherapy (P = 0.005) and chest radiotherapy (P = 0.017) were associated with increased 1-year mortality, whereas hyperlipidemia (P = 0.018) was protective.
  
  
  CONCLUSIONS
  In this study of cancer patients with MI, medical therapy with aspirin and β-blockers was associated with improved survival. The authors have no funding, financial relationships, or conflicts of interest to disclose.
authors.affiliation: Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, USA. syusuf@mdanderson.org
authors.forename: Syed Wamique
authors.initials: SW
authors.lastname: Yusuf
authors.forename: Nicoleta
authors.initials: N
authors.lastname: Daraban
authors.forename: Nadia
authors.initials: N
authors.lastname: Abbasi
authors.forename: Xiudong
authors.initials: X
authors.lastname: Lei
authors.forename: Jean-Bernard
authors.initials: JB
authors.lastname: Durand
authors.forename: Iyad N
authors.initials: IN
authors.lastname: Daher
mesh_terms: D000046:Academic Medical Centers; D054058:Acute Coronary Syndrome / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D001241:Aspirin / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D015999:Multivariate Analysis; D009204:Myocardial Revascularization / Q000009:adverse effects / Q000401:mortality; D009369:Neoplasms / Q000453:epidemiology* / Q000401:mortality; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013781:Texas / Q000453:epidemiology; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000401:mortality; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D002317:Cardiovascular Agents; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin